TRUFILL n-BCA Liquid Embolic System 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 Codman Neuro 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2014-01-23
  • 사례 출판 날짜
    2014-01-23
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: codman neuro trufill n-bca liquid embolic system the united states food and drug administration (fda) has issued a medical device safety alert concerning trufill n-bca liquid embolic system [product code: 631400 & 631500], manufactured by codman neuro. according to the fda, trufill n-bca is indicated for embolization of cerebral arteriovenous malformations (avms) when presurgical devascularization is desired. in october 2013, the manufacturer identified an incorrect statement in the product's instructions for use (ifu) that described suggested mixing ratios for use in certain treatment conditions. the manufacturer is informing physicians of this incorrect statement and updating the product's ifu. the product's ifu incorrectly noted: "a 2:1 (67% ethiodized oil / 33% nbca) for feeding pedicle injections close to the nidus at high flow rates where venous opacification occurs on contrast injections within 1/2 second." the correct information should have stated: "a 2:1 (67% ethiodized oil / 33% nbca) for intranidal injections without av fistulae or high flow rates in order to more deeply penetrate the nidus." the use of incorrectly mixed product can result in the liquid mixture solidifying too slowly in unintended areas, which may lead to embolization or reflux into arteries and pulmonary vessels. this could result in significant impact to the patient, including neurological deficits, pulmonary emboli and possibly death. the manufacturer advises all affected users to review the correction notice and other product literature to ensure proper mixing procedures are followed. according to the local supplier, the affected products were not distributed in hong kong. for details, please refer to fda websites:http://www.Fda.Gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm382556.Htm http://www.Fda.Gov/safety/recalls/ucm382496.Htm if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 23 january 2014.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 의료기기 분류등급
  • 제품 설명
    Medical Device Safety Alert: Codman Neuro TRUFILL n-BCA Liquid Embolic System
  • Manufacturer

Manufacturer